Merimepodib

Merimepodib (VX-497) is a novel noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. It displays broad spectrum antiviral activities.